» Articles » PMID: 11158745

Impact of the Order of Initiation of Fluconazole and Amphotericin B in Sequential or Combination Therapy on Killing of Candida Albicans in Vitro and in a Rabbit Model of Endocarditis and Pyelonephritis

Overview
Specialty Pharmacology
Date 2001 Feb 13
PMID 11158745
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

In vitro time-kill studies and a rabbit model of endocarditis and pyelonephritis were used to define the impact that the order of exposure of Candida albicans to fluconazole (FLC) and amphotericin B (AMB), as sequential and combination therapies, had on the susceptibility of C. albicans to AMB and on the outcome. The contribution of FLC-induced resistance to AMB for C. albicans also was assessed. In vitro, AMB monotherapy rapidly killed each of four C. albicans strains; FLC alone was fungistatic. Preincubation of these fungi with FLC for 18 h prior to exposure to AMB decreased their susceptibilities to AMB for 8 to >40 h. Induced resistance to AMB was transient, but the duration of resistance increased with the length of FLC preincubation. Yeast sequentially incubated with FLC followed by AMB plus FLC (FLC-->AMB+FLC) showed fungistatic growth kinetics similar to that of fungi that were exposed to FLC alone. This antagonistic effect persisted for at least 24 h. Simultaneous exposure of C. albicans to AMB and FLC [AMB+FLC(simult)] demonstrated activity similar to that with AMB alone for AMB concentrations of > or =1 microg/ml; antagonism was seen using an AMB concentration of 0.5 microg/ml. The in vitro findings accurately predicted outcomes in our rabbit infection model. In vivo, AMB monotherapy and treatment with AMB for 24 h followed by AMB plus FLC (AMB-->AMB+FLC) rapidly sterilized kidneys and cardiac vegetations. AMB+FLC(simult) and FLC-->AMB treatments were slower in clearing fungi from infected tissues. FLC monotherapy and FLC-->AMB+FLC were both fungistatic and were the least active regimens. No adverse interaction was observed between AMB and FLC for the AMB-->FLC regimen. However, FLC-->AMB treatment was slower than AMB alone in clearing fungi from tissues. Thus, our in vitro and in vivo studies both demonstrate that preexposure of C. albicans to FLC reduces fungal susceptibility to AMB. The length of FLC preexposure and whether AMB is subsequently used alone or in combination with FLC determine the duration of induced resistance to AMB.

Citing Articles

CAF to the Rescue! Potential and Challenges of Combination Antifungal Therapy for Reducing Morbidity and Mortality in Hospitalized Patients With Serious Fungal Infections.

Jacobs S, Chaturvedi V Open Forum Infect Dis. 2024; 11(11):ofae646.

PMID: 39544494 PMC: 11561589. DOI: 10.1093/ofid/ofae646.


In Vitro-In Vivo Correlation of Posaconazole-Amphotericin B Combination against : In Vitro Interacting Concentrations Are Associated with In Vivo Free Drug Levels.

Meletiadis J, Beredaki M, Elefanti A, Pournaras S, Muller A J Fungi (Basel). 2023; 9(4).

PMID: 37108889 PMC: 10146624. DOI: 10.3390/jof9040434.


Antifungal Combinations against Species: From Bench to Bedside.

Fioriti S, Brescini L, Pallotta F, Canovari B, Morroni G, Barchiesi F J Fungi (Basel). 2022; 8(10).

PMID: 36294642 PMC: 9605143. DOI: 10.3390/jof8101077.


Multicenter prospective observational study of fungal keratitis in Japan: analyses of in vitro susceptibility tests for combinations of drugs.

Kimura K, Inoue Y, Asari S, Sunada A, Ohashi Y, Shimomura Y Jpn J Ophthalmol. 2022; 66(3):240-253.

PMID: 35348983 DOI: 10.1007/s10384-022-00907-2.


Techniques for the Assessment of In Vitro and In Vivo Antifungal Combinations.

Bidaud A, Schwarz P, Herbreteau G, Dannaoui E J Fungi (Basel). 2021; 7(2).

PMID: 33557026 PMC: 7913650. DOI: 10.3390/jof7020113.


References
1.
Louie A, Liu W, Miller D, Sucke A, Liu Q, Drusano G . Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and.... Antimicrob Agents Chemother. 1999; 43(12):2831-40. PMC: 89573. DOI: 10.1128/AAC.43.12.2831. View

2.
Martin E, Maier F, Bhakdi S . Antagonistic effects of fluconazole and 5-fluorocytosine on candidacidal action of amphotericin B in human serum. Antimicrob Agents Chemother. 1994; 38(6):1331-8. PMC: 188207. DOI: 10.1128/AAC.38.6.1331. View

3.
Durack D, Beeson P, Petersdorf R . Experimental bacterial endocarditis. 3. Production and progress of the disease in rabbits. Br J Exp Pathol. 1973; 54(2):142-51. PMC: 2072580. View

4.
Bannatyne R, Cheung R . Discrepant results of amphotericin B assays on fresh versus frozen serum samples. Antimicrob Agents Chemother. 1977; 12(4):550. PMC: 429966. DOI: 10.1128/AAC.12.4.550. View

5.
Jorgensen J, Alexander G, Graybill J, Drutz D . Sensitive bioassay for ketoconazole in serum and cerebrospinal fluid. Antimicrob Agents Chemother. 1981; 20(1):59-62. PMC: 181632. DOI: 10.1128/AAC.20.1.59. View